Tesla(TSLA.US)及馬斯克涉誇大自駕技術安全性面臨股東集體訴訟
Tesla(TSLA.US)及行政總裁馬斯克面臨來自股東的集體訴訟,指控涉嫌誇大電動車Autopilot(自動輔助駕駛)及Full Self-Driving(全自動駕駛)的有效性及安全性。
股東稱,Tesla在過去四年間以虛假及誤導性陳述欺騙股東,隱瞞這些技術造成嚴重事故及傷亡的風險,而隨著美國國家公路交通安全管理局(NHTSA)及美國證交會(SEC)開始調查這些技術後,導致Tesla股價大幅下跌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.